Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 9.72% | -1.65% | 6.67% | 12.18% | -14.86% |
| Total Depreciation and Amortization | 0.41% | -1.22% | -1.61% | -3.86% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.79% | 37.43% | 14.00% | -36.44% | -27.38% |
| Change in Net Operating Assets | 339.22% | -203.20% | 135.33% | -370.90% | -40.42% |
| Cash from Operations | 50.45% | -33.33% | 41.64% | -36.89% | -36.95% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -32.38% | -13.44% | -36.46% | 29.87% | 54.00% |
| Total Debt Repaid | 0.00% | 0.00% | -5.54% | -2.85% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -34.82% | -15.65% | -37.63% | 29.43% | 58.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 90.53% | -371.48% | 24.53% | -29.72% | 691.26% |
